Muir-Torre syndrome (MTS), a rare subtype of Lynch syndrome, is mostly autosomal dominant, which is caused by germline mutations in DNA mismatch repair (MMR) genes, the resulting microsatellite instability (MSI) of which increases the risk of developing sebaceous and other visceral tumors. Several reports have showed an association between immunosuppressive agents and the progression of latent MTS. In this report, we described a 41-year-old man with a history of kidney transplantation, having a rapid growth of the nodule on the anterior chest under immunosuppressive therapy, which was histologically proved to be sebaceous carcinoma. Systemic evaluation for visceral malignancies revealed sigmoid adenocarcinoma. These findings were consistent with the clinical diagnosis of MTS. Histological findings showed an absence of MMR proteins, including MSH2 and MSH6 both in the sebaceous carcinoma and sigmoid adenocarcinoma on immunohistochemical (IHC) analysis. A frame-shift mutation of c.229_230delAG (p. Ser77fs) in the MSH2 exon 2 in the lesion was detected by next-generation sequencing (NGS) analysis. This case report not only reveals a new site of MSH2 mutation in this family of East Asian descent but also highlights the importance of adequate diagnosis for Muir-Torre syndrome, as well as further prevention of the development of latent visceral tumors in kidney transplant recipients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264542PMC
http://dx.doi.org/10.3389/fonc.2021.681780DOI Listing

Publication Analysis

Top Keywords

muir-torre syndrome
12
case report
8
msh2 exon
8
visceral tumors
8
sebaceous carcinoma
8
sigmoid adenocarcinoma
8
report frameshift
4
frameshift mutation
4
msh2
4
mutation msh2
4

Similar Publications

Sebaceous carcinoma in immunosuppressed patients: a narrative review.

Arch Dermatol Res

January 2025

Department of Dermatology, Columbia University Irving Medical Center, 161 Ft Washington Ave, 12th Floor, New York, NY, 10032, USA.

Sebaceous carcinoma is a rare cutaneous malignancy of sebaceous glands, but it is up to 25-fold more common in immunosuppressed individuals. In this narrative review, we examine the current literature on the pathogenesis, incidence, risk factors, prognosis, treatment, and surveillance of sebaceous carcinoma in immunosuppression and highlight practical considerations for providers who care for these patients. Increased incidence may be related to decreased immune surveillance, susceptibility to an unknown viral trigger, microsatellite instability, immunosuppressive medications, and unmasking of occult Muir-Torre Syndrome.

View Article and Find Full Text PDF

Sebaceous gland hyperplasia is a benign cutaneous entity commonly seen in older men. Occasionally, it can develop in young patients on immunosuppression with cyclosporine or in adolescent boys in the peripubertal age group. It is extremely rare in young children with no reports of eyelid involvement.

View Article and Find Full Text PDF

A novel lynch syndrome kindred with hereditary adrenal cortical carcinoma.

Cancer Genet

November 2024

Eastern Virginia Medical School, Norfolk, VA, USA; Virginia Oncology Associates, Norfolk, VA, USA.

Article Synopsis
  • Adrenal cortical carcinoma (ACC) is a rare and aggressive cancer, often with a poor prognosis, underscoring the necessity for early detection and treatment through surgical resection.
  • This case study features a 59-year-old man with a hereditary form of ACC linked to Muir-Torre syndrome, indicating a connection between Lynch syndrome and increased risk of this malignancy, particularly in families with a history of ACC.
  • The findings stress the importance of targeted cancer screening for individuals with Lynch syndrome and the critical need for distinct germline and somatic genetic testing in cancer cases to better inform treatment options.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!